During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Marina Kremyanskaya, Icahn School of Medicine at Mount Sinai, New York, US. We asked, Is the hepcidin-mimetic PTG‑300 a promising treatment for therapeutic phlebotomy-dependent polycythemia vera (PV)?

Currently, patients with PV require frequent phlebotomy. Kremyanskaya discusses promising results from a phase II clinical trial evaluating the safety and efficacy of PTG-300, a novel hepcidin-mimetic, in patients with PV who received three or more phlebotomies up to 6 months before treatment. Kremyanskaya highlights that the need for phlebotomy was eliminated in patients treated with PTG-300. In addition, PTG-300 was well tolerated.

Hosted on Acast. See acast.com/privacy for more information.